Diagnostic DNA kits specialist Devyser Diagnostics AB (STO:DVYSR) and Thermo Fisher Scientific Inc (NYSE:TMO), a provider of science services, announced on Wednesday a new collaboration agreement to promote laboratory services to pharmaceutical companies.

Their joint objective is to support pharmaceutical development projects by leveraging Devyser's unique assays within its CLIA-certified laboratory.

The partnership will focus on marketing Devyser's laboratory services to support and advance research and development initiatives within the pharmaceutical sector.

Fredrik Alpsten, CEO of Devyser, expressed the company's commitment to aiding pharmaceutical companies in developing new and improved therapies. He anticipates that Thermo Fisher's global network and extensive reach will serve as a strong platform for collaborations with global pharmaceutical companies, aligning with Devyser's strategy to expand its presence in the United States.

Devyser established its CLIA-certified laboratory in the United States in spring 2023 and secured CLIA certification from the Centers for Medicare and Medicaid Services (CMS) in May 2023. The lab is based in Atlanta, Georgia.